Why carnitine deficiency is relevant in the treatment of patients with neurological disorders


L-carnitine, carnitine deficiency, treatment, polyprotective effect, Cardonat.

How to Cite

Svyrydova, N. (2015). Why carnitine deficiency is relevant in the treatment of patients with neurological disorders. East European Journal of Neurology, (1(1), 33-38. https://doi.org/10.33444/2411-5797.2015.1(1).33-38


L-carnitine holds an important place among the medicines that affect the metabolism,. Carnitine-based medications are highly effective and can seriously contribute to a regression of clinical manifestations of the disease or decrease the intensity of the disease. The metabolic activity of Cardonat Sperco Ukraine, the anabolic properties of its components, as well as their cardio-, neuro-, and hepato¬ and nephroprotective properties give reason to consider Cardonat it the first polyprotector anabolic. All of the above makes it possible to use Cardonat in cardio-neurological, gastroenterological and urological practices.



Копелевич В.М. Витаминоподобные соединения L-карнитин и ацетил-L-карнитин: от биохимических исследований к меди- цинскому применению. Укр. биохим. журн. 2005. 77, 25–45.

Румянцева С.А., Ступин В.А., Афанасьев В.В. Рациональная фармакотерапия при сосудистой патологии.-М-Сб. «Медкни- га». 2014.-339 с.

Maccari F., Ramacci M. T. Antagonism of doxorubicin cardiotoxicity by carnitine is specific of the L-diasteroisomer. Biomedicine. 35 : 65—67. 1981.

Liedtke A. J., Nellis St. H., Whitesell L. F. Effects of camitine isomers on fatty acid metabolism in ischemic swine hearts. Circul. Res. 48 : 859—866. 1981.

Watanabe S., Ajisaka R., Masuoka Т., Yamanouchi Т., Saitou Т., Тоуата М., Takeyasu N., Sakamoto K., Sugishita Y. Effects of L- and DL-carnitine on patients with impaired exercise tolerance. Jpn. Heart J. 36 (3) : 319—331. 1995.

C. Mingorance, R. Rodríguez-Rodríguez, M. Justo at al. Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders// Health Risk Manag. 2011; 7: 169–176.

Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci. 2004;1033:79–91

Revenco D, Morgan JP. Metabolic modulation and cellular therapy of cardiac dysfunction and failure. J Cell Mol Med. 2009;13(5):811–825.

Anon Acetyl-L-carnitine. Monograph. Altern Med Rev. 2010;15(1):76–83.

Paulson DJ, Traxler J, Schmidt M, et al. Protection of the ischemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport and fatty acid oxidation. Cardiovasc Res. 1986;20:536–541.

Paulson DJ, Schmidt MJ, Romens J, Shug AL. Metabolic and physiologic differences between zeroflow and low-flow myocardial ischemia: effects of L-acetylcarnitine. Basic Res Cardo. 1984;79(5):551–561

Retter AS. Carnitine and its role in cardiovascular disease. Heart Dis. 1999;1(2):108–113.

Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol. 2000;95(2):75–83

Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res. 2001;51(1):21–29.

Hiatt WR. Carnitine and peripheral arterial disease. Ann N Y Acad Sci. 2004;1033:92–98.

Andreozzi GM. Propionyl l-carnitine: intermittent claudication and peripheral arterial disease. Expert Opin Pharmacother. 2009;10(16):2697–2707.

Свищенко Е.П., Лысенко Г.И. клиническая характеристика кардоната у больных гипертонической болезнью/ Г.И. Лысен- ко, Е.П. Свищенко // УМЖ. – 2005. – № 2 (46). – С.14–16.

Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J. 1992;13(2):251–255.

Spagnoli LG, Corsi M, Villaschi S, Palmieri G, Maccari F. Myocardial carnitine deficiency in acute myocardial infarction. Lancet. 1982;1(8286):1419–1420.

Lesnefsky EJ, He D, Moghaddas S, Hoppel CL. Reversal of mitochondrial defects before ischemia protects the aged heart. FASEB J. 2006;20(9):1543–1545.

Cui J, Das DK, Bertelli A, Tosaki A. Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. Mol Cell Biochem. 2003;254(1–2):227–234.

Chiddo A, Gaglione A, Musci S, et al. Hemodynamic study of intravenous propionyl-L-carnitine in patients with ischemic heart disease and normal left ventricular function. Cardiovasc Drugs Ther.1991;5(Suppl 1):107–111.

Lango R, Smoleński RT, Rogowski J, et al. Propionyl-L-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. Cardiovasc Drugs Ther.2005;19(4):267–275.

Digiesi V ,CantinI F ,BisI G ,Guarino G ,Brodbeck B L-carnitine adjuvant therapy in essential hypertension// La Clinica Terapeutica-1994- Vol.194/- P. 391-395

Nakamura J., Koh N., Sakakibara F. et al.// Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats. J. Pharmacol. Exp. Ther. 1998. 287, P. 897-902.

Soneru I.L., Khan T., Orfalian Z. et al. // Acetyl-L-carnitine effects on nerve conduction and glycemic regulation in experimental diabetes. Endocr. Res. 1997. 23, P.27-36.

Masahiro Ohsawaa, Shigeo Miyataa, Anna Carlssonb and Junzo Kameia,Preventive effect of acetyl-L-carnitine on the thermal hypoalgesia in streptozotocin-induced diabetic mice Eur J Pharmacol. 2008 Jul 7;588(2-3):213-6

Sima AA Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data.CNS Drugs. 2007;21 Suppl 1:13-23.

Calvani M., Benatti P., Mancinelli A., D’lddio S., Giordano V., Koverech A., Amato A., Brass E. P. Carnitine replacement in end-stage renal disease and hemodialysis. Ann. N. Y. Acad. Sci. 1033 : 52—66. 2004.

Sayed-Ahmed M. M., Eissa M. A., Kenawy S. A., Mostafa N., Calvani M., Osman A. M. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy. 50(4): 162—170. 2004.

Matera M, Bellinghieri G, Costantino G. History of L-carnitine: implications for renal disease//J Ren Nutr. 2003 Jan;13(1):2-14.

Brass E. P. Camitine and sports medicine: use or abuse? Ann. N. Y. Acad. Sci. 1033 : 67—78. 2004.

Dubelaar M. L., Lucas C. M., Hulsmann W. C. Acute effect of L-carnitine on skeletal muscle force tests in dogs. Am. J. Physiol. 260(2, pt 1): E189—E193. 1991.

Murray, C.J.; Lopez, A.D. Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997, 349, 1269–1276.

Deshpande, J.K.; Siesjo, B.K.; Wieloch, T. Calcium accumulation and neuronal damage in the rat hippocampus following cerebral ischemia. J. Cereb. Blood Flow Metab 1987, 7, 89–95.

MacManus, J.P.; Buchan, A.M.; Hill, I.E.; Rasquinha, I.; Preston, E. Global ischemia can cause DNA fragmentation indicative of apoptosis in rat brain. Neurosci. Lett 1993, 164, 89–92.

Leist, M.; Jaattela, M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol 2001, 2, 589–598.

Picconi, B.; Barone, I.; Pisani, A.; Nicolai, R.; Benatti, P.; Bernardi, G.; Calvani, M.; Calabresi, P. Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: The role of endogenous acetylcholine. Neuropharmacology 2006, 50, 917–923.

Flanagan, J.L.; Simmons, P.A.; Vehige, J.; Willcox, M.D.; Garrett, Q. Role of carnitine in disease. Nutr. Metab. (Lond.) 2010, 7, 30–43.

Virmani, A.; Binienda, Z. Role of carnitine esters in brain neuropathology. Mol. Aspects Med 2004, 25, 533–549.

Al-Majed A.A., Sayed-Ahmed M.M., Al-Omar F.A. et al. Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus. Clin Exp Pharmacol Physiol. 2006;33(8):725–733.

Rosenthal RE, WiUiams R, Bogaert YE, et al. Prevention of postischemic canine neurological injury through potentiation of brain energy metabolism by acetyl-Lcarnitine. Stroke. 1992;23:1312–1317

Aureli T, Miccheh A, Di Coceo ME, et al. Effect of acetyl-L- carnitine on recovery of brain phosphorus metabolites and lactic acid level during reperfusion after cerebral ischemia in the rat – study by 13P- and lH-NMR spectroscopy. Brain Res. 1994;643:92–99.

Jalal FY, Böhlke M, Maher TJ. Acetyl-L-carnitine reduces the infarct size and striatal glutamate outflow following focal cerebral ischemia in rats. Ann N Y Acad Sci. 2010;1199:95–104.

Ozmen E1, Ozsoy SY, Donmez N, Ozsoy B, Yumuşak N.The protective effect of L-carnitine against hippocampal damage due to experimental formaldehyde intoxication in rats //Biotech Histochem. 2014 Jul;89(5):336-41

Fedotova AV, Mironova OP, Fedin AI L-carnitine treatment patients with chronic cerebral ischemia. // 2013;113(5):48-53.

Lolic M.M., Fiskum G., Rosenthal R.E. Neuroprotective effects of acetyl-L-carnitine after stroke in rats. Ann Emerg Med (United States) June 1997, 29 (6) p. 758–65.

Thal L.J., Carta A., Clarke W.R. et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer’s disease. Neurology. 1996; 47: 705–711.

Gecele M.. Acetyl L-carnitine in aged subjects with major depression: clinical efficacy and effects on the circadian rhythm of cortisol / M. Gecele, G. Francesetti, A. Meluzzi // Dementia. 1991. Vol. 2. P. 333–337.

Никокнов В.В. Энергетические субстраты в комплексном лечении хронической ишемии мозга// Укр. мед.часопис.- 2004.- №2 (40).- С.119-121

Беловол А.Н. Перспективы фармакологической коррекции в кардиологии и неврологии//Ліки України.- 2009.- №2 (128).- С.67-70

Дзяк Л.А., Голик В.А. Опыт использования препарата Кардонат у пациентов с дисциркуляторной энцефалопатией 1 стадии на фоне патологии магистральных артерий головы // Здоровье Украины.-2003.-№10(71).- С.29.